Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

Uhlig, M.
Evaluation of nephroprotective effects of glucagon-like peptide 1 receptor in renal ischemia reperfusion injury
Humanmedizin; [ Diplomarbeit ] Medical University of Graz; 2019. pp. 93 [OPEN ACCESS]


Authors Med Uni Graz:
Eller Kathrin
Eller Philipp

Liraglutide affects various mechanisms that are decisive in IRI like the RAAS, reactive oxygen species and inflammation (155). Therefore we aimed to test the hypothesis that liraglutide exhibits a nephroprotektive effect in a murine model of renal IRI. Here, we followed two approaches: first, we compared the outcome of GLP-1R -/- mice with wild-type mice, and secondly wild-type mice with liraglutide treatment (200μg/kgBW/d starting 7 days prior to surgery) versus vehicle. We hypothesized an improved outcome of wild-type compared to the knock-out mice and a further improvement with the administration of liraglutide as a protective agonist. The results of this study suggest a protective effect of GLP-1R activation in renal IRI. There was a significant increase in the retention parameters urea (p = 0.043) and creatinine (p = 0.0473) in GLP-1R deficient mice, on the other hand there was an alleviation of renal IRI when the GLP-1 receptor was activated. In animals pretreated with liraglutide we observed significantly decreased serum urea (p = 0.0149) and BUN levels (p = 0.03). Unfortunately, this improvement in outcomes was not directly reflected in the histology, although a significantly higher number of macrophages (p = 0.0286) was detected in mice treated with liraglutide. The following L-Arg stain showed a non-significant trend (p = 0.1111) towards the benefit of the M2 phenotype, which at least suggests that the majority of the additional macrophages might have been of the M2/repair type In summary, the absence of the GLP-1R aggravated the impairment of kidney functions in renal IRI, as well as the activation of the GLP-1R by liraglutide ameliorated the AKI and preserved kidney functions. Therefore, we conclude that liraglutide has a reno-protective effect in mice subjected to renal IRI. Not only does this further elucidate the underlying mechanism of the improved renal outcome that was seen in large-scale clinical trials, but also reveals the potential that Liraglutide might have for the treatment of AKI.

© Med Uni GrazImprint